biopharmaceutical

MannKind's CEO will present at Oppenheimer Conference on February 26 while the company enrolls first patient in pediatric diabetes trial for its Afrezza insulin therapy.

Akebia Therapeutics will release 2025 financial results February 26, 2026, followed by a conference call discussing operational performance and strategic updates.

Merck partners with Mayo Clinic to use AI and advanced analytics for drug discovery, focusing on inflammatory bowel disease, atopic dermatitis, and multiple sclerosis treatment development.

HCW Biologics raised $1.5M through a unit offering and seeks shareholder approval to reduce warrant exercise price from $2.41 to $0.6055 per share.

BridgeBio Pharma awarded 76,701 restricted stock units to 34 new employees as inducement grants under Nasdaq rules, vesting over four years with continued employment.

Inventiva raises $172.5M, boosting cash position to €99.3M and extending runway through mid-2027 to fund MASH therapy development.

Ocular Therapeutix announces Phase 3 results for SOL-1 wet AMD treatment on February 17, 2026. AXPAXLI data presentation follows at Macula Society Annual Meeting.

Aardvark Therapeutics granted 152,338 stock options to six new hires with exercise prices of $13.48-$12.67, vesting over four years with a one-year cliff.

ANI Pharmaceuticals will report 2025 results on February 27, 2026, reaffirming confidence in meeting or exceeding guidance for revenues, EBITDA, and earnings per share.

OKYO Pharma prices $20M share offering to fund clinical development of urcosimod for neuropathic corneal pain treatment, advancing Phase 2b/3 trial.